Presentation is loading. Please wait.

Presentation is loading. Please wait.

Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307.

Published byGabriella Dawson Modified over 8 years ago

Similar presentations

Presentation on theme: "Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307."— Presentation transcript:

1 Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307

2 Characteristics of studies on pharmacological/herbal interventions included in review Gillies CL, et al. BMJ 2007;334:299-307

3 Characteristics of studies on pharmacological and lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307

4 Information used for the meta-analyses of interventions to prevent or delay type 2 diabete Gillies CL, et al. BMJ 2007;334:299-307

5 Flowchart of literature search and meta-analysis Gillies CL, et al. BMJ 2007;334:299-307

6 Meta-analysis of effect of lifestyle interventions on risk of developing type 2 diabetes Gillies CL, et al. BMJ 2007;334:299-307

7 Meta-analyses of effect of pharmacological and herbal interventions on risk of developing type 2 diabetes Gillies CL, et al. BMJ 2007;334:299-307

8 Results of meta-regression analyses of interventions to prevent or delay type 2 diabetes Gillies CL, et al. BMJ 2007;334:299-307

9 Reported adverse events possibly attributable to pharmacological interventions to prevent or delay type 2 diabetes Gillies CL, et al. BMJ 2007;334:299-307

Download ppt "Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:299-307."

Similar presentations

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Addressing missing participant data in systematic reviews: Part I – Dichotomous outcomes Elie Akl, Shanil Ebrahim, Bradley Johnston, Pablo Alonso, Matthias.

Addressing missing participant data in systematic reviews: Part I – Dichotomous outcomes Elie Akl, Shanil Ebrahim, Bradley Johnston, Pablo Alonso, Matthias.
Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Lars Sjöström et al N Engl J Med 2004; 351: 2683- 93 Characteristics of the Subjects at the Time of Matching and at the Time of the Inclusion Examination.

Lars Sjöström et al N Engl J Med 2004; 351: Characteristics of the Subjects at the Time of Matching and at the Time of the Inclusion Examination.
Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.

Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis by David C. Burgess, Michael.
1 Lecture 10: Meta-analysis of intervention studies Introduction to meta-analysis Selection of studies Abstraction of information Quality scores Methods.

1 Lecture 10: Meta-analysis of intervention studies Introduction to meta-analysis Selection of studies Abstraction of information Quality scores Methods.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.
Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis by Kayalvili Mugunthan, Treasure.

Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis by Kayalvili Mugunthan, Treasure.
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:306-313.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
Why wasn’t a beta-blocker tested as first-line therapy?

Why wasn’t a beta-blocker tested as first-line therapy?
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Diabetes hazard rates by number of visits with reported statin use.

Diabetes hazard rates by number of visits with reported statin use.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Jun M, et al. Lancet 2010 Epub May 10

Jun M, et al. Lancet 2010 Epub May 10
Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Similar presentations

Ads by Google